Huiting Li, MS

Department of Oncology, Shanghai Medical College, Fudan University

Shanghai, Shanghai

Disclosures:

Employment: none
Compensation: none
Ownership: none
Leadership: none

Presentations

Sep 30

1226 - Feasibility of Aumolertinib followed by SRT in EGFR+ NSCLC Patients with Intracranial Oligo-Progression: A Phase II, Prospective Study

08:20am - 08:25am ET